Drug Trial Radar · NCT01681953
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis
Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Aug 2012
Primary completion
May 2014
Study completion May 2014
Sponsor
- Lead sponsor
- Zymenex A/SIndustry
- Sponsor type
- Industry
- Collaborators
- European Commission
- First posted
- Sep 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis
Conditions
- Alpha-Mannosidosis
Interventions
LamazymDrug
ERT, i.v. infusions weekly
PlaceboDrug
Infusions weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of oligosaccharides in serumTime frame: Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks
- The number of steps climbed in 3 minutes (3-minute stair climb test)Time frame: Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
Copenhagen, Denmark
Hôpital Femme Mère Enfant, Lyon, 59 boulevard Pinel
Bron, France
Hôpital Trousseau, Service de neuropédiatrie, Centre Référence des Maladies Lysosomales, 26 avenue du Docteur Arnold Netter
Paris, France
Universitätsmedizin Mainz, Zentrum für Kinder- und Jugendmedizin, Langenbeckstrasse 1
Mainz, Germany
The Children's Memorial Health Institute Warsaw, Department of Metabolic Diseases, Al Dzieci Polskich 20
Warsaw, Poland
Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.